JP2020524510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524510A5 JP2020524510A5 JP2019570555A JP2019570555A JP2020524510A5 JP 2020524510 A5 JP2020524510 A5 JP 2020524510A5 JP 2019570555 A JP2019570555 A JP 2019570555A JP 2019570555 A JP2019570555 A JP 2019570555A JP 2020524510 A5 JP2020524510 A5 JP 2020524510A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- binding
- fixa
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101150117115 V gene Proteins 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709970.6A GB201709970D0 (en) | 2017-06-22 | 2017-06-22 | Bispecific antigen-binding molecules |
| GB1709970.6 | 2017-06-22 | ||
| PCT/EP2018/066836 WO2018234575A1 (en) | 2017-06-22 | 2018-06-22 | Bispecific antibodies for factor ix and factor x |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524510A JP2020524510A (ja) | 2020-08-20 |
| JP2020524510A5 true JP2020524510A5 (enExample) | 2021-07-29 |
| JP7378298B2 JP7378298B2 (ja) | 2023-11-13 |
Family
ID=59523569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570555A Active JP7378298B2 (ja) | 2017-06-22 | 2018-06-22 | 第ｉｘ因子および第ｘ因子に対する二重特異性抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11919969B2 (enExample) |
| EP (1) | EP3642244A1 (enExample) |
| JP (1) | JP7378298B2 (enExample) |
| CN (1) | CN110753704B (enExample) |
| GB (1) | GB201709970D0 (enExample) |
| WO (1) | WO2018234575A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3126384T3 (da) * | 2014-04-01 | 2021-01-18 | Adimab Llc | Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse |
| CN110248964B (zh) | 2017-02-01 | 2024-08-27 | 诺和诺德股份有限公司 | 促凝血抗体 |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| ES2901683T3 (es) | 2018-12-21 | 2022-03-23 | Kymab Ltd | Anticuerpo biespecífico FIXAXFX con cadena ligera común |
| GB2590642B (en) | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| JP2022532388A (ja) | 2019-05-15 | 2022-07-14 | カイマブ・リミテッド | 改善されたラムダ抗体 |
| US20230151115A1 (en) * | 2020-03-31 | 2023-05-18 | University Public Corporation Osaka | Multispecific antibody and method for producing same |
| IL298632A (en) * | 2020-06-02 | 2023-01-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Non-human animals genetically modified with a common light chain immunoglobulin locus |
| CN114113602B (zh) * | 2020-08-28 | 2024-07-02 | 香港城市大学深圳研究院 | 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物 |
| KR102749341B1 (ko) | 2022-07-08 | 2025-01-06 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
| CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
| CN116333145B (zh) * | 2023-04-14 | 2023-11-07 | 北京基科晟斯医药科技有限公司 | 结合活化凝血因子ix的抗体 |
| GB202316779D0 (en) * | 2023-11-01 | 2023-12-13 | Ucl Business Ltd | Antigen binding protein |
| WO2026036047A1 (en) * | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| WO1999003496A1 (en) * | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| WO2007003421A2 (en) | 2005-07-05 | 2007-01-11 | Glaxo Group Limited | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| AU2011266843C9 (en) | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| US10066019B2 (en) | 2012-10-12 | 2018-09-04 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| BR112016009954A2 (pt) | 2013-11-04 | 2017-12-05 | Univ California | terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação |
| NZ720353A (en) | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| JP6698102B2 (ja) * | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| WO2017072310A1 (en) | 2015-10-30 | 2017-05-04 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| JP6954842B2 (ja) | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| IL260937B2 (en) | 2016-02-06 | 2024-07-01 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| RU2770006C2 (ru) | 2016-05-16 | 2022-04-14 | Такеда Фармасьютикал Компани Лимитед | Антитела к фактору ix padua |
| AU2017303205B2 (en) | 2016-07-29 | 2024-08-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| IL265144B2 (en) | 2016-09-06 | 2024-10-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| JP7227146B2 (ja) | 2016-11-23 | 2023-02-21 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体 |
| CN110248964B (zh) | 2017-02-01 | 2024-08-27 | 诺和诺德股份有限公司 | 促凝血抗体 |
| US20210284715A1 (en) | 2017-02-06 | 2021-09-16 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| EP3621643A4 (en) | 2017-05-11 | 2021-07-21 | Atreca, Inc. | ANTIBODY ANTI-MALARIA BOUND WITH CIRCUMSPOROZOID PROTEIN |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| TW202423960A (zh) | 2017-09-29 | 2024-06-16 | 日商中外製藥股份有限公司 | 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑 |
| US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
| ES2901683T3 (es) | 2018-12-21 | 2022-03-23 | Kymab Ltd | Anticuerpo biespecífico FIXAXFX con cadena ligera común |
-
2017
- 2017-06-22 GB GBGB1709970.6A patent/GB201709970D0/en not_active Ceased
-
2018
- 2018-06-22 CN CN201880040433.6A patent/CN110753704B/zh active Active
- 2018-06-22 US US16/625,109 patent/US11919969B2/en active Active
- 2018-06-22 WO PCT/EP2018/066836 patent/WO2018234575A1/en not_active Ceased
- 2018-06-22 EP EP18735237.2A patent/EP3642244A1/en active Pending
- 2018-06-22 JP JP2019570555A patent/JP7378298B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524510A5 (enExample) | ||
| US11649295B2 (en) | Asymmetric multispecific antibodies | |
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| JP2019527553A5 (enExample) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2020508655A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| NZ601583A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| JP2012518425A5 (enExample) | ||
| HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
| JP2010502183A5 (enExample) | ||
| JP2011505810A5 (enExample) | ||
| JP2015519375A5 (enExample) | ||
| JP2019502694A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2013535191A5 (enExample) | ||
| JP2021502984A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2017509323A5 (enExample) | ||
| JP2020522475A5 (enExample) | ||
| JP2018515453A5 (enExample) | ||
| JP2022527812A (ja) | リラグルチドに対する抗体およびその使用 |